Simulations Plus (SLP): Customer relationships anchoring an annual-license business in AI-driven drug modeling

Simulations Plus sells mechanistic drug-discovery and development software plus consulting services to pharmaceutical, biotech, academic and government clients, monetizing primarily through annual software licenses and professional services engagements. The company’s economics are driven by recurring license renewals, a services mix that supports product adoption, and a geographically diversified revenue base concentrated in the Americas. Investors evaluating SLP should view it as a licensor with a renewal-heavy, low-concentration customer book that benefits when large AI drug-discovery players adopt its modeling technology.

For a quick look at the platform and market posture, visit the NullExposure home page: https://nullexposure.com/.

What the business model actually looks like to customers and investors

Simulations Plus operates as a software licensor and professional services seller. The company recognizes most software revenue at license activation because licenses are typically annual or shorter, and a smaller portion of revenue is recognized ratably where the company hosts software as a service. This creates a contract profile of short-term, renewal-driven receipts with predictable seasonal cadence—renewals often recur in the same quarter year-after-year—while services provide both revenue diversification and a client lock-in effect through ongoing project work.

• Contracting posture: Predominantly annual licenses recognized at unlock; SaaS arrangements exist but represent a small portion of revenue.
• Revenue mix and customer economics: Software accounted for a majority of revenue while services contributed meaningful recurring professional work that supports product adoption.
• Geographic footprint and diversification: The customer base is global, with roughly 73% of revenue in the Americas, ~18% in EMEA, and ~9% in APAC, reducing single-region risk while concentrating most revenue in North America.
• Concentration and credit risk: The client base is highly fragmented and the company did not derive material revenue from any single customer in FY2025, indicating low counterparty concentration risk.
• Counterparty profile: Customers include large enterprises, government and academic/regulatory agencies, and private biotech/AI drug discovery firms—so contractual terms, procurement cycles, and validation requirements vary materially by segment.
• Business criticality and maturity: For many program-level customers (drug development teams or AI discovery groups), the software is an important modeling tool but not typically sole-source platform infrastructure; this yields stickiness via renewals and services rather than complete platform entrenchment.

Notable customer relationships highlighted publicly

Google DeepMind: Management acknowledged that major AI drug-discovery players, including Google DeepMind, license some footprint of Simulations Plus’s software, indicating the company’s tools are used by leading AI research groups in drug discovery. This was discussed on the company’s Q2 FY2026 earnings call transcript reported by InsiderMonkey on May 3, 2026. (Source: InsiderMonkey Q2 FY2026 earnings call transcript, 2026-05-03.)

Recursions: Management named “Recursions” among historical AI drug-discovery customers that license at least part of Simulations Plus’s suite, underscoring traction with specialized AI-driven biotech companies. This mention came from the same Q2 FY2026 earnings call transcript published by InsiderMonkey on May 3, 2026. (Source: InsiderMonkey Q2 FY2026 earnings call transcript, 2026-05-03.)

What these named relationships imply for revenue quality and go-to-market

The fact that AI-first drug-discovery groups and large AI research labs license Simulations Plus’s software is a validation of the product’s technical fit for computational modeling workflows; however, the company’s FY2025 disclosure that no single customer is material indicates these contracts are important but not dominant in revenue terms. The licensing of foot‑print features to AI groups suggests a product strategy that supports modular adoption: customers can license specific capabilities without flipping an entire discovery stack.

• Commercial implication: Having leading AI groups as customers raises the company’s profile and improves cross-sell opportunities into larger pharmaceutical programs, while the annual-license model preserves renewal discipline.
• Operational implication: Short-term license durations require steady renewal execution and a services organization that can convert trials and pilots into paying licenses.

Key risks investors should monitor around customer dynamics

• Renewal risk and timing volatility: Because most licenses are annual and recognized at unlock, quarters can see lumpy revenue if renewals shift; investors should monitor renewal rates and any quarter-to-quarter timing shifts.
• Concentration through cohort behavior: While no individual client was material in FY2025, loss of multiple mid-size renewals or a slowdown among AI discovery labs could disproportionately affect near-term growth given the license-recognition mechanics.
• SaaS penetration and revenue recognition: SaaS arrangements are a small portion of revenue; a strategic move to hosted models would change revenue recognition and could pressure near-term margins if not executed profitably.
• Customer diversity: The customer base spans large enterprise, government/regulatory, and small AI biotechs, which is a strength for diversification but increases the complexity of sales cycles and contract terms.

Operational constraints that shape customer economics

The company’s filings and disclosures offer direct signals about how relationships run in practice: licenses are short-term and often renewed annually, SaaS is a minority format, services are a material adjunct to software sales, the client base is fragmented (no material single client), and the business is geographically diversified with the Americas dominating revenue. These are company-level operating characteristics that inform revenue predictability, contract flexibility, and sales resource allocation—none of these constraints are attributed to an individual named customer in the filings.

Investment takeaway and next step

Simulations Plus is a renewal-driven licensor with credible adoption among advanced AI drug-discovery groups and traditional pharma alike. The firm’s mixed software-and-services model produces steady recurring revenue complemented by consulting work that supports renewals and customer expansion. Key value drivers for investors are renewal rates, expansion into SaaS hosting, and continued penetration of AI-led discovery teams.

For investors and operators wanting ongoing monitoring and more granular customer signals, keep this page on your watchlist and explore further at https://nullexposure.com/.